Impact of prior immune checkpoint inhibitor on trastuzumab deruxtecan in HER2-positive advanced gastric cancer: exploratory analysis of the EN-DEAVOR study - PubMed
4 days ago
- #HER2-positive gastric cancer
- #trastuzumab deruxtecan
- #immune checkpoint inhibitor
- HER2-positive advanced gastric cancer (AGC) presents significant therapeutic challenges due to molecular heterogeneity.
- Exploratory analysis of EN-DEAVOR study evaluated T-DXd effectiveness and safety relative to prior ICI timing.
- Patients were stratified by prior ICI exposure: within 2 months (Group A), >2 months (Group B), and no prior ICI (Group C).
- Group A showed the longest median rwPFS (6.9 months) vs. Group B (4.6 months) and Group C (4.2 months).
- Risk of progression was significantly lower in Group A vs. Group B (HR: 0.6; P = .0074).
- ORR was highest in Group A (54.9%) vs. Group B (30.8%) and Group C (43.4%).
- Grade ≥ 3 AEs were more frequent in Group B (58.7%) vs. Group A (50.8%) and Group C (43.8%).
- No new safety signals were observed.
- Initiating T-DXd within 2 months post-ICI may enhance efficacy without affecting safety.